CompletedPhase 2NCT00677092
Pilot Study of Imatinib Mesylate to Treat Nephrogenic Systemic Fibrosis
Studying Nephrogenic systemic fibrosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Massachusetts General Hospital
- Principal Investigator
- Jonathan Kay, MDMassachusetts General Hospital
- Intervention
- Imatinib mesylate(drug)
- Enrollment
- 12 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2007 – 2009
Study locations (1)
- Massachusetts General Hospital, Boston, Massachusetts, United States
Collaborators
Novartis Pharmaceuticals
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00677092 on ClinicalTrials.gov